Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
intravenous immunoglobulin + recombinant human thrombopoietin
- Development stage
- Phase 2
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination therapy consisting of intravenous immunoglobulin (IVIG) and recombinant human thrombopoietin (rhTPO). IVIG is a blood product containing pooled IgG antibodies from healthy donors, used primarily for its immunomodulatory effects in autoimmune and inflammatory diseases. Recombinant human thrombopoietin is a full-length glycosylated cytokine produced by Chinese hamster ovary cells that mimics endogenous thrombopoietin to stimulate the production of megakaryocytes and platelets via activation of the MPL receptor. The combination may be used in clinical settings where both immune modulation (to reduce platelet destruction) and stimulation of platelet production are desired, such as severe or refractory immune thrombocytopenia or chemotherapy-induced thrombocytopenia[1][2][5]. Both components have distinct mechanisms—IVIG modulates immune responses while rhTPO directly stimulates platelet generation.
- Other names
- IVIG + rhTPOIVIG plus recombinant human thrombopoietinintravenous immunoglobulin and rhTPO
02
Targets
Complement component C5aFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)FCGRT (Neonatal crystallizable fragment receptor)TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on intravenous immunoglobulin + recombinant human thrombopoietin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on intravenous immunoglobulin + recombinant human thrombopoietin.